Product Description
Lexicon was developing lx-1606, an oral TPH Inhibitor for Carcinoid Syndrome. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01104415)
Mechanisms of Action: TPH Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Lexicon
Company Location: THE WOODLANDS TX 77381
Company CEO: Lonnel Coats
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Malignant Carcinoid Syndrome|Carcinoid Tumor|Serotonin Syndrome|Other
Phase 2: Neuroendocrine Tumors|Serotonin Syndrome|Carcinoid Tumor|Malignant Carcinoid Syndrome|Colitis, Ulcerative
Phase 1: Serotonin Syndrome|Malignant Carcinoid Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| LX1606-104 | P1 |
Completed |
Serotonin Syndrome|Malignant Carcinoid Syndrome |
2013-09-01 |
2019-03-19 |
||
| NCI-2018-00294 | P2 |
Completed |
Neuroendocrine Tumors|Serotonin Syndrome|Carcinoid Tumor|Malignant Carcinoid Syndrome |
2020-10-15 |
2025-04-11 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
| LX1606.1-202-CS | P2 |
Completed |
Carcinoid Tumor|Serotonin Syndrome|Malignant Carcinoid Syndrome |
2014-06-01 |
2019-03-18 |
Treatments |
|
| LX1606.1-203-CS | P2 |
Completed |
Carcinoid Tumor|Serotonin Syndrome|Malignant Carcinoid Syndrome |
2014-02-12 |
2019-03-19 |
Treatments |
|
| 2009-016973-13 | P2 |
Completed |
Unknown |
2014-02-12 |
2025-05-06 |
Treatments |
|
| 2011-003532-32 | P2 |
Completed |
Colitis, Ulcerative |
2013-09-03 |
2022-03-13 |
Treatments |
|
| TELEPATH | P3 |
Completed |
Carcinoid Tumor|Malignant Carcinoid Syndrome|Serotonin Syndrome |
2018-09-12 |
18% |
2019-09-18 |
Primary Endpoints|Treatments |
| TELEPATH (Telotristat Etiprate â Expanded Treatment for Patients with Carcinoid Syndrome Symptoms) | P3 |
Completed |
Unknown |
2018-09-12 |
18% |
2022-03-13 |
Treatments |
| TELECAST | P3 |
Completed |
Carcinoid Tumor|Serotonin Syndrome|Malignant Carcinoid Syndrome |
2016-03-29 |
2019-03-20 |
Treatments |
|
| 2013-001543-31 | P3 |
Completed |
Unknown |
2016-03-29 |
2022-03-13 |
Treatments |
|
| LX1606.1-301-CS | P3 |
Completed |
Carcinoid Tumor|Serotonin Syndrome|Malignant Carcinoid Syndrome |
2016-03-21 |
2019-03-19 |
Treatments |
|
| TELESTAR (Telotristat Etiprate for Somatostatin Analogue Refractory Carcinoid Syndrome) | P3 |
Completed |
Other |
2016-03-17 |
2025-07-01 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/19/2024 |
PubMed |
Use of perioperative telotristat in a patient with carcinoid heart disease. |
|
02/07/2024 |
PubMed |
Does Telotristat Have a Role in Preventing Carcinoid Heart Disease? |
|
04/20/2023 |
PubMed |
The role of serotonin inhibition within the treatment of carcinoid syndrome. |